In malignant melanoma, the expression of insulin?like growth factor?II mRNA?binding protein 3 (IMP?3), a member of the insulin?like growth factor mRNA?binding protein family, has been demonstrated, but not in other benign skin lesions.
Scientific Publications
Comprehensive clinicopathological and molecular analysis of primary malignant melanoma of the oesophagus
In the present study, the researchers sought to illustrate the clinicopathological features, genetic alterations and therapeutic targets of primary malignant melanoma of the oesophagus (PMME).
Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases
Although melanoma brain metastases (MBM) tend to respond to systemic therapy concordantly with extracranial metastases, little is known about differences in immune cell and vascular content between the brain and other metastatic sites.
The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression
The transcription factor NRF2 is the major mediator of oxidative stress responses and is closely connected to therapy resistance in tumors harboring activating mutations in the NRF2 pathway.